Business Wire

ADARA announces expansion into the Nordics and plans for further European growth

Share

ADARA, the leader in predictive traveller intelligence, today announces its expansion into the Nordic market for the first time, with the appointment of Jonas Jonsborg as Regional Manager, Nordics ADARA. In addition to the hire, ADARA also announces new recent data partnerships with Momondo, HotelsCombined and Cheapflights, which will further bolster its presence in Europe and support brands in the region.

Comprising over 850 million monthly unique traveller profiles across more than 200 leading travel brands, ADARA’s travel data co-op offers a holistic view of traveller behaviour and preferences along the entire customer journey. Since expanding into the region in 2013, ADARA has established a strong presence in Europe with the appointment of Curtis Nishijima as Managing Director, EMEA in 2018 and with key hires in the UK, Germany, France and Spain. ADARA has also seen an increase in its EMEA data profiles of 38% year on year, furthering bolstering their data presence in the region.

Building on the success in these markets, ADARA is now strengthening its presence in the Nordics, one of the fastest-growing travel markets in EMEA. Tourism in the Nordics has seen a significant rise in recent years; since 2014 the region had an annual growth of 6% - 8.5% in the number of hotel nights. The expansion seeks to enable travel brands and agencies to tap into the increased demand by tourists to and from the Nordic region by offering holistic data insights that can be used to create personalised marketing campaigns based on the complete view of the traveller.

The depth and applicability of ADARA’s data go beyond the travel and tourism industries. Other sectors in the Nordics such as luxury retail, financial services and automotive can also take advantage of ADARA’s understanding of traveller purchase behaviour and ADARA can provide these brands with solutions that improve marketing performance and help achieve deeper personalisation using actionable data.

In his new role, Jonas will spearhead ADARA’s expansion into the Nordic markets, drawing on his extensive understanding and experience in data and advertising technology. Jonas has previously held executive positions at Adform, Microsoft, Meetrics and Audience Project.

Jonas Jonsborg, Regional Manager at ADARA Nordics said: The Nordic market is experiencing a huge gap, one that can only be filled by ADARA. The breadth and depth of the data is unparalleled, and will be invaluable to Nordic partners. I look forward to leveraging my experience in the Nordics and strong belief in ADARA’s value proposition to grow the business and establish new data partners in the region.”

Curtis Nishijima, Managing Director, EMEA said “Jonas has an exceptional range of skills that make him the perfect person to spearhead our Nordic expansion. He has a strong knowledge of the region and a deep understanding of our industry.

-ENDS-

About Momondo
Momondo is a travel fare aggregator and travel fare metasearch engine headquartered in Copenhagen. Momondo also operates a travel information blog, Inspiration. The website is part of the Kayak.com subsidiary of Booking Holdings.

About Hotelscombined
HotelsCombined, a unit of Booking Holdings, is a hotel metasearch engine founded in 2005. The site operates in over 42 languages, handles 130 different currencies and aggregates more than 2 million deals from hundreds of travel sites and hotel chains.

About Cheapflights
Cheapflights is a travel fare aggregator and travel fare metasearch engine headquartered in London, UK. The website is part of the Kayak.com subsidiary of Booking Holdings. Its websites publish flight prices, and compare prices from suppliers, including major airlines, through tiny travel agents.

About ADARA
ADARA. Know What Travellers Need Next.

ADARA empowers the world's leading travel brands to grow the industry together. Built on the world's richest travel data co-op, ADARA offers people-based insights for travel companies. Clients get a value-based understanding of their relationship with their customers, with travel patterns, trends and behavior from more than 850 million monthly unique traveler profiles across more than 200 of the world's top travel brands. ADARA delivers critical intelligence to activate personalisation and relevance throughout the customer journey for sustainable growth. Its offerings span the three core pillars – Learn, Act, Measure & Modify – to drive measurable outcomes at the customer level. https://www.adara.com

Contact information

For more information please contact:
Ben Tozer / Louise Watson
adara@propellergroup.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing